Biodegradation, biodistribution and toxicity of chitosan

被引:1348
作者
Kean, T. [2 ]
Thanou, M. [1 ]
机构
[1] Kings Coll London, Div Pharmaceut Sci, London SE1 9NH, England
[2] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA
关键词
Chitosan; Biodegradation; Biodistribution; Toxicity; Delivery; In vitro; In vivo; ACIDIC MAMMALIAN CHITINASE; N-SUCCINYL-CHITOSAN; POORLY ABSORBABLE DRUGS; O-SULFATE CHITOSAN; TAY-SACHS-DISEASE; IN-VITRO; MOLECULAR-WEIGHT; PHOTOCROSSLINKABLE CHITOSAN; ABSORPTION ENHANCERS; ASPERGILLUS-NIGER;
D O I
10.1016/j.addr.2009.09.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chitosan is a natural polysaccharide that has attracted significant scientific interest during the last two decades. It is a potentially biologically compatible material that is chemically versatile (-NH2 groups and various M-w). These two basic properties have been used by drug delivery and tissue engineering scientists to create a plethora of formulations and scaffolds that show promise in healthcare. Despite the high number of published studies, chitosan is not approved by the FDA for any product in drug delivery, and as a consequence very few biotech companies are using this material. This review will aim to provide information on these biological properties that affect chitosan's safe use in drug delivery. The term "Chitosan" represents a large group of structurally different chemical entities that may show different biodistribution, biodegradation and toxicological profiles. Here we aim to review research in this area and critically discuss chitosan's potential to be used as a generally regarded as safe (GRAS) material. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 98 条
[71]   N-acetyl-β-D-hexosaminidase from Trichomonas vaginalis:: substrate specificity and activity of inhibitors [J].
Sanon, A ;
Tournaire-Arellano, C ;
El Hage, SY ;
Bories, C ;
Caujolle, R ;
Loiseau, PM .
BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 (05) :245-248
[72]   Chitosans as absorption enhancers of poorly absorbable drugs 3:: Influence of mucus on absorption enhancement [J].
Schipper, NGM ;
Vårum, KM ;
Stenberg, P ;
Ocklind, G ;
Lennernäs, H ;
Artursson, P .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (04) :335-343
[73]   Chitosans as absorption enhancers for poorly absorbable drugs .1. Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells [J].
Schipper, NGM ;
Varum, KM ;
Artursson, P .
PHARMACEUTICAL RESEARCH, 1996, 13 (11) :1686-1692
[74]   Potential applications of chitosan in veterinary medicine [J].
Senel, S ;
McClure, SJ .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (10) :1467-1480
[75]  
Sgouras D., 1990, EVALUATION BIOCOMPAT
[76]   Evaluation of the clearance characteristics of bioadhesive systems in humans [J].
Soane, RJ ;
Frier, M ;
Perkins, AC ;
Jones, NS ;
Davis, SS ;
Illum, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 178 (01) :55-65
[77]   In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery [J].
Sonaje, Kiran ;
Lin, Yu-Hsin ;
Juang, Jyuhn-Huarng ;
Wey, Shiaw-Pyng ;
Chen, Chiung-Tong ;
Sung, Hsing-Wen .
BIOMATERIALS, 2009, 30 (12) :2329-2339
[78]   CONJUGATE OF MITOMYCIN-C WITH N-SUCCINYL-CHITOSAN - IN-VITRO DRUG-RELEASE PROPERTIES, TOXICITY AND ANTITUMOR-ACTIVITY [J].
SONG, YH ;
ONISHI, H ;
NAGAI, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 98 (1-3) :121-130
[79]   NN'-DIACETYLCHITOBIASE ACTIVITY IN TAY-SACHS DISEASE AND SANDHOFFS DISEASE [J].
STIRLING, JL .
BIOCHEMICAL JOURNAL, 1974, 141 (02) :597-599
[80]  
Suzuki YS, 1998, J NUCL MED, V39, P2161